VivoSim Labs (FRA:4OR) Cyclically Adjusted Price-to-FCF: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4OR VivoSim Labs Inc FRA:4OR
28 GF Score
Price €3.49
GF Value €14.93
! 6 Warning Signs
View Full Analysis

What is VivoSim Labs Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


VivoSim Labs  (FRA:4OR) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


VivoSim Labs Cyclically Adjusted Price-to-FCF Related Terms


VivoSim Labs Cyclically Adjusted Price-to-FCF Historical Data

* Premium members only.

The historical data trend for VivoSim Labs's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VivoSim Labs Cyclically Adjusted Price-to-FCF Chart

VivoSim Labs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

VivoSim Labs Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:4OR vs SPRC, GOVX, SXTP: Cyclically Adjusted Price-to-FCF Comparison

For the Biotechnology subindustry, VivoSim Labs's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VivoSim Labs Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VivoSim Labs's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where VivoSim Labs's Cyclically Adjusted Price-to-FCF falls into.


FRA:4OR
28GF Score
VivoSim Labs Inc FRA:4OR
Cyclically Adjusted Price-to-FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VivoSim Labs Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

VivoSim Labs's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, VivoSim Labs's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.879/333.9520*333.9520
=-0.879

Current CPI (Jun. 2026) = 333.9520.

VivoSim Labs Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -15.634 241.428 -21.626
201612 -17.204 241.432 -23.797
201703 -16.198 243.801 -22.188
201706 -21.911 244.955 -29.872
201709 -11.731 246.819 -15.872
201712 -12.246 246.524 -16.589
201803 -10.111 249.554 -13.530
201806 -12.955 251.989 -17.169
201809 -7.802 252.439 -10.321
201812 -7.178 251.233 -9.541
201903 -9.022 254.202 -11.852
201906 -9.928 256.143 -12.944
201909 -8.621 256.759 -11.213
201912 -0.965 256.974 -1.254
202003 -5.338 258.115 -6.906
202006 -4.195 257.797 -5.434
202009 -11.095 260.280 -14.235
202012 -2.143 260.474 -2.748
202103 -2.784 264.877 -3.510
202106 -1.840 271.696 -2.262
202109 -2.548 274.310 -3.102
202112 -4.259 278.802 -5.101
202203 -1.996 287.504 -2.318
202206 -3.242 296.311 -3.654
202209 -3.249 296.808 -3.656
202212 -4.012 296.797 -4.514
202303 -6.298 301.836 -6.968
202306 -6.771 305.109 -7.411
202309 -4.094 307.789 -4.442
202312 -4.250 306.746 -4.627
202403 -2.939 312.332 -3.142
202406 -2.268 314.175 -2.411
202409 -1.587 315.301 -1.681
202412 -1.143 315.605 -1.209
202503 -1.157 319.799 -1.208
202506 -1.370 322.561 -1.418
202509 -0.778 324.800 -0.800
202512 -0.743 324.054 -0.766
202603 -0.734 330.213 -0.742
202606 -0.879 333.952 -0.879

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is VivoSim Labs (FRA:4OR) Overvalued in 2026?

Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued. The current stock price of €3.49 is trading 76.6% below its estimated GF Value™ of €14.93.

Key valuation signals for FRA:4OR:

  • Cyclically Adjusted Price-to-FCF:
  • GF Value™: €14.93 vs. price of €3.49 (76.6% below fair value)
  • GF Score™: 28/100 with 6 warning signs

No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


VivoSim Labs Business Description

Other Exchanges VIVS:USA
Address 11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
28GF Score

Get the complete analysis for FRA:4OR

Cyclically Adjusted Price-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.49
Price
€14.93
GF Value